Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort.

First-line targeted HER2-based targeted therapy Among the 46 patients who received first-line chemotherapy plus HER2-targeted therapy, the ORR was numerically higher in the CLDN18.2-high group (83.3% versus 68.4%) but did not reach statistical significance ( P = 0.40; Supplementary Table S3 , available at https://doi.org/10.1016/j.esmoop.2025.106053 ), and no differences were observed after stratification by PD-L1 expression ( P >0.9; Supplementary Table S6 , available at https://doi.org/10.1016/j.esmoop.2025.106053 ).

also in 111,027 other papers